EWのチャート
EWの企業情報
| symbol | EW |
|---|---|
| 会社名 | Edwards Lifesciences Corp （EW エドワ―ズライフサイエンス） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 エドワーズ・ライフサイエンス(Edwards Lifesciences Corporation)は欠陥心臓弁の置換、または修復に応用する心臓弁システムおよび修復製品の製造者である。同社は構造的心疾患および重症ケアのモニタリングなどの患者中心のイノベーションに従事する。同社のセグメントは米国、ヨーロッパ、日本、他の地域を含む。同社の製品分野は外科心臓弁療法、経カテーテル心臓弁、およびクリティカルケアを含む。同社は入院中の患者の心臓血管機能を測定するために使用される血行動態モニタリングシステムを提供する。同社の経カテーテル心臓弁製品は米国、シンガポール、スイスに生産される。クリティカルケア製品はプエルトリコとドミニカ共和国にある施設で生産される。同社の子会社はEdwards Lifesciences Asset Management Corporation、Edwards Lifesciences CardiAQ LLC.、 Valtech Cardio Inc.とRed Hill Insurance Corporationを含む。 エドワ―ズ・ライフサイエンスは重度の循環器疾患治療用の医療器具メ―カ―。心臓弁膜症などの循環器疾患や心臓血管疾患、また、救命救急診療技術、抹消血管障害の治療に焦点を置く。主要製品は、弁膜症治療用心臓弁｢カ―ペンタ―・エドワ―ズ・ペリマウント｣､人工弁輪、肺動脈カテ―テルなど。製品は約100カ国で販売される。 Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. Edwards Lifesciences is driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. |
| 本社所在地 | One Edwards Way Irvine CA 92614 USA |
| 代表者氏名 | Michael A. Mussallem |
| 代表者役職名 | Chairman of the Board Chief Executive Officer |
| 電話番号 | +1 949-250-2500 |
| 設立年月日 | 36404 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 12800人 |
| url | www.edwards.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 1155.80000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 39817.57000 |
| 売上高 | 売上高（百万ドル） 3722.80000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 39454.87000 |
| 当期純利益 | 当期純利益（百万ドル） 747.00000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Edwards Lifesciences Corp revenues increased 8% to $3.72B. Net income before extraordinary items decreased 16% to $738M. Revenues reflect Transcatheter Heart Valve Therapy segment increase of 13% to $2.29B Critical Care segment increase of 12% to $674.5M United States segment increase of 8% to $2.06B Rest of the world segment increase of 14% to $396M. |
EWのテクニカル分析
EWのニュース
Capital Counsel Llc Buys Edwards Lifesciences Corp, Amazon. ... 2022/02/16 22:38:44 GuruFocus
Related Stocks: EW , AMZN , EFX , VNT , HON , TSLA , KD ,
Was The Smart Money Right About Edwards Lifesciences Corporation (EW)? 2022/02/04 04:12:34 Insider Monkey
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Edwards Lifesciences upgraded at UBS on prospects in TAVR market 2022/02/02 17:33:12 Seeking Alpha
Following a decline of more than 15% in January, Edwards Lifesciences (EW) has bounced back after UBS upgraded the cardiac equipment company to Buy from Neutral, citing its potential in
Vascular Access Devices Market is Expected to Surge at a Significant CAGR of 6.64% and is also Contemplated to Reach Upto USD 6.13 Billion by 2026, Estimates DelveInsight 2022/01/27 18:00:00 Benzinga
Las Vegas, USA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Vascular Access Devices Market is Expected to Surge at a Significant CAGR of 6.64% and is also Contemplated to Reach Upto USD 6.13 Billion by 2026, Estimates DelveInsight The Vascular Access Device market is anticipated to grow tremendously in the coming years due to many factors which include the rising prevalence of end-stage renal diseases and the rising number of vascular access surgeries, these are striving the Vascular Access Devices demand, thus driving the growth of Vascular Access Device market. DelveInsight''s Vascular Access Devices Market Insights and Forecast report provides the current and forecast Vascular Access Devices, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Vascular Access Devices. Some of the essential takeaways from the Vascular Access Devices Market report: According to DelveInsight analysis, North America is expected to dominate the overall Vascular Access Devices Market during the forecast period.
Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q4 2021 Results - Earnings Call Transcript 2022/01/27 00:06:04 Seeking Alpha
Raymond James Trust N.A. Buys 339 Shares of Edwards Lifesciences Co. (NYSE:EW) 2021/12/01 13:34:47 Transcript Daily
Raymond James Trust N.A. boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,621 shares of the medical research companys stock after purchasing an additional 339 shares []
Exchange Traded Concepts LLC Purchases 1,369 Shares of Edwards Lifesciences Co. (NYSE:EW) 2021/11/30 17:08:41 Dakota Financial News
Exchange Traded Concepts LLC increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,113 shares of the medical research companys stock after acquiring an additional 1,369 shares during []
Wendell David Associates Inc. Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) 2021/11/30 15:52:42 Dakota Financial News
Wendell David Associates Inc. raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,325 shares of the medical research companys stock after buying an additional 1,200 shares during the period. []
Monday 11/29 Insider Buying Report: CION, EW 2021/11/29 18:53:13 One News Page
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Foundry Partners LLC 2021/11/29 12:42:41 Dakota Financial News
Foundry Partners LLC lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 11.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 9,656 shares of the medical research companys stock after selling 1,303 shares during the period. Foundry Partners LLCs holdings in Edwards Lifesciences were worth []
Exchange Traded Concepts LLC Purchases 1,369 Shares of Edwards Lifesciences Co. (NYSE:EW) 2021/11/30 17:08:41 Dakota Financial News
Exchange Traded Concepts LLC increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,113 shares of the medical research companys stock after acquiring an additional 1,369 shares during []
Wendell David Associates Inc. Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) 2021/11/30 15:52:42 Dakota Financial News
Wendell David Associates Inc. raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,325 shares of the medical research companys stock after buying an additional 1,200 shares during the period. []
Monday 11/29 Insider Buying Report: CION, EW 2021/11/29 18:53:13 One News Page
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Foundry Partners LLC 2021/11/29 12:42:41 Dakota Financial News
Foundry Partners LLC lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 11.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 9,656 shares of the medical research companys stock after selling 1,303 shares during the period. Foundry Partners LLCs holdings in Edwards Lifesciences were worth []
Transcatheter Aortic Valve Replacement (TAVR) Market 2021-2028 Booming Revenue in Upcoming Future| Edwards Lifesciences, Medtronic, Boston Scientific, Meril Life Sciences, Bracco, JenaValve Technology, St. Jude Medical 2021/11/29 12:41:18 OpenPR
Transcatheter Aortic Valve Replacement Market is projected to boom at a CAGR +12% by the timeline of 2021-28. Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure to replace a narrowed aortic valve that fails to open properly (aortic valve